InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,864.67
(
0.40%
)
US TECH 100
19,783.20
(
0.68%
)
Dow Jones
43,275.91
(
0.09%
)
Brent Oil
72.94
(
0.00%
)
Bitcoin
68,312.05
(
-0.16%
)
Post# of 19276
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

findit

Send PM Follow Ignore
Followers 150
Posts 15066
Boards Moderated 1
Alias Born 07/07/2002

findit

Member Level

Re: Rivet post# 17428

Wednesday, 05/19/2004 3:23:15 PM

Wednesday, May 19, 2004 3:23:15 PM

Post# of 19276
DOR is being helped by passage of Project BioShield.

DOR BioPharma, Inc. is a development-stage biopharmaceutical company specializing in the clinical testing of products that meet unmet medical needs. Through its Biodefense Division, DOR is developing vaccines against ricin toxin and botulinum toxin. DOR's lead therapeutic product, orBec (oral beclomethasone dipropionate), is in a Phase III clinical trial for the treatment of intestinal graft-versus-host disease.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up